简体
简体中文
繁體中文

biote BTMD 深 沪

等待开盘 11-17 09:30:00 美东时间

0.9603

-0.105

-9.83%

华盛通华盛通
立即下载
  • 最 高1.08
  • 今 开1.05
  • 成交量 6.50万股
  • 最 低 0.9557
  • 昨 收 1.065
  • 总市值 3445.31万
  • 52周最高 2.90
  • 市盈率 静 1.30
  • 换手率 0.18%
  • 52周最低 0.9557
  • 委 比 -15.61%
  • 总股本 3587.75万
  • 历史最高 12.08
  • 量 比 0.81
  • 振 幅 11.67%
  • 历史最低 0.9557
  • 每 手 1
  • 风险率 0.51%

个股概要

财务分析

公司资料

相关新闻

分红派息

  • 分时图
  • 日k
  • 周k
  • 月k

相关新闻

更多
  • SynAct Pharma CEO Acquires 20,313 Shares

    The latest update is out from SynAct Pharma AB ( ($SE:SYNACT) ). SynAct Pharma ...

    11-16 23:32

  • MetaVia Reports Preclinical DA-1726 Data Comparing Metabolic Therapies

    MetaVia ( ($MTVA) ) has issued an announcement. MetaVia is a clinical-stage bio...

    11-16 22:27

  • Acrivon Reports Third Quarter 2026 Financial Results and Business Highlights

    Acrivon Therapeutics reported third-quarter 2026 financial results and highlighted progress in its oncology and immunology pipelines. The company expanded its focus into immunology and inflammation, leveraging its AI-driven AP3 platform to identify novel therapies. Key developments include ACR-525, a JAK1 inhibitor targeting eosinophilic esophagitis, and ACR-2316, a WEE1/PKMYT1 inhibitor showing promising safety and efficacy in lung cancers. ACR-...

    11-16 21:05

  • Exicure Announces Filing of Notification of Late Filing on Form 12b-25

    Exicure, Inc. announced it filed a Notification of Late Filing on Form 12b-25 with the SEC due to additional time needed to review its accounting for certain assets and liabilities. The company expects to file its Q3 2026 Form 10-Q within the five-day extension period under Rule 12b-25. Exicure, a biotechnology company focused on nucleic acid therapies, is exploring strategic alternatives to maximize stockholder value following its restructuring.

    11-16 21:00

  • Daré Bioscience Receives Approximately $852,000 in Additional Grant Funding

    Daré Bioscience received an additional $851,796 under a $10.7 million grant to develop a novel non-hormonal intravaginal contraceptive for women in low- and middle-income countries. This payment is the second-to-last tranche of the grant, supporting ongoing research and development efforts. The company aims to address unmet needs in reproductive health by providing greater choice and autonomy for women.

    11-16 14:09

  • MeiraGTx Announces Oral Presentation at ObesityWeek 2026

    MeiraGTx will present its AAV-BDNF program at ObesityWeek 2026, targeting severe early-onset obesity caused by BDNF haploinsufficiency. The study demonstrates that a single hypothalamic injection of AAV-BDNF restored metabolic and neurobehavioral function in mouse models, with long-term efficacy and safety. This intervention addresses both obesity and neurobehavioral symptoms, offering potential for transformative treatment in rare genetic disord...

    11-16 12:00

  • Zymeworks Announces $200 Million Share Repurchase Authorization

    Zymeworks has launched a second 2026 share repurchase program, authorizing up to $200 million in repurchases through 2028, with $140 million expected to be spent by then. The program offers flexibility to adjust repurchase pace based on market conditions and cash flow. The company aims to balance capital allocation across R&D, M&A, and share repurchases to enhance shareholder value. The program is funded by existing cash and near-term inflows, in...

    11-16 11:00

  • Nextbiomedical Filing Lists Nexpowder Approvals, Nexsphere-F Licensing Agreements

    An announcement from Nextbiomedical Co. Ltd. ( ($KR:389650) ) is now available....

    11-16 10:24

  • Neurizon Opens A$2.0 Million Share Purchase Plan

    Pharmaust Limited ( ($AU:NUZ) ) has shared an update. Neurizon Therapeutics is ...

    11-16 06:15

  • Mesoblast Showcased at ASX Premier Investor Day Event

    Mesoblast Limited, a global leader in allogeneic cellular medicines for inflammatory diseases, highlighted its transformation into a commercial-stage biotech company at the ASX Investor Day. The presentation emphasized the continued growth of Ryoncil® (remestemcel-L-rknd) and the potential to leverage its cellular therapy platform across multiple high-value indications. Key priorities include expanding RYONCIL into adult acute graft-versus-host d...

    11-15 23:16